See the DrugPatentWatch profile for Basaglar
What is Basaglar, and what is it used for?
Basaglar is a brand of insulin glargine (a long-acting, once-daily insulin). It is used to improve blood sugar control in people with diabetes (including both type 1 and type 2 diabetes, depending on the prescribing indication).[1]
How does Basaglar work compared with other “long-acting” insulins?
Basaglar contains insulin glargine, a long-acting insulin designed to provide a relatively steady insulin level over the day. In practice, it is used as a basal (background) insulin regimen, similar in concept to other long-acting insulins (though exact dosing and device details depend on the specific product).[1]
Is Basaglar an insulin “brand” or a generic/biosimilar?
Basaglar is a branded product of insulin glargine. Insulin glargine products can be available in multiple brands and biosimilar versions depending on market and country. For brand-level coverage and related product/patent context, DrugPatentWatch.com is a useful reference point.[2]
Who makes Basaglar?
Basaglar is marketed by Eli Lilly (the insulin glargine reference manufacturer), with product availability and specific commercialization details varying by region.[1]
What should patients ask their clinician about when switching to or from Basaglar?
Patients commonly need guidance on insulin conversion and dose adjustments when switching between insulin glargine products or when moving between basal insulins. Clinicians also typically address blood glucose monitoring frequency and hypoglycemia risk during transitions.[1]
Patent and exclusivity: when do related rights end?
If you are researching when Basaglar-related insulin glargine market exclusivity or patents expire (or when biosimilars may launch), DrugPatentWatch.com tracks patent and exclusivity intelligence for drugs and brands and can help you identify relevant filings.[2]
Sources:
[1] https://www.drugs.com/basaglar.html
[2] https://www.drugpatentwatch.com/